Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease–Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities

Interstitial lung disease (ILD), a group of diffuse parenchymal lung disorders classified together based on specific clinical, radiologic, and histopathologic features, is often associated with significant morbidity and mortality and is a common manifestation in connective tissue disease (CTD) (1). ILD often arises within the context of a specific exposure or is associated with an underlying CTD. The CTDs are a spectrum of systemic autoimmune disorders with significant clinical heterogeneity characterized by immunemediated organ dysfunction, and the lung is a frequent target. All CTD patients are at risk of developing ILD, and those with systemic sclerosis (SSc), polymyositis/ dermatomyositis (PM/DM), and rheumatoid arthritis (RA) are at particularly high risk (1,2). ILD may develop at any point in the natural history of CTD, is most frequently identified in the setting of an established CTD, and may also be the first clinically apparent manifestation of occult CTD. Determining whether a patient has a diagnosis of CTDassociated ILD is important, as this knowledge may impact treatment decisions, guide surveillance for other concomitant clinical features, and help with assessment of prognosis (3).

[1]  M. Sauler Form, Function, and Dysfunction: Airway Diseases Are Associated With Increased Risk for Rheumatoid Arthritis , 2019, Arthritis & rheumatology.

[2]  G. Rossi,et al.  The Lung in Rheumatoid Arthritis , 2018, Arthritis & rheumatology.

[3]  Y. Yamaguchi,et al.  Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients , 2018, Rheumatology.

[4]  L. Yarmus,et al.  Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure , 2018, Respiration.

[5]  M. Roth,et al.  Reliability and Minimal Clinically Important Differences of FVC. Results from the Scleroderma Lung Studies (SLS‐I and SLS‐II) , 2017, American journal of respiratory and critical care medicine.

[6]  M. Baron,et al.  Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate) , 2017, Annals of the rheumatic diseases.

[7]  A. Nicholson,et al.  Short‐Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis , 2017, Arthritis & rheumatology.

[8]  M. Remy-Jardin,et al.  Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease , 2017, PloS one.

[9]  A. Fischer,et al.  Pulmonary fibrosis in connective tissue disease (CTD): urgent challenges and opportunities. , 2017, QJM : monthly journal of the Association of Physicians.

[10]  F. Maldonado,et al.  Transbronchial cryobiopsy for diffuse parenchymal lung disease: a state-of-the-art review of procedural techniques, current evidence, and future challenges. , 2017, Journal of thoracic disease.

[11]  Barbara L. Goldstein,et al.  High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival. , 2017, Respiratory medicine.

[12]  Yi Zheng,et al.  Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease , 2017, Clinical Rheumatology.

[13]  R. Hubbard,et al.  Surgical lung biopsy for the diagnosis of interstitial lung disease in England: 1997–2008 , 2016, European Respiratory Journal.

[14]  F. Martinez,et al.  Six-SOMAmer Index Relating to Immune, Protease and Angiogenic Functions Predicts Progression in IPF , 2016, PloS one.

[15]  R. Elashoff,et al.  Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind, parallel group, randomised controlled trial , 2016, The Lancet. Respiratory medicine.

[16]  E. Matteson,et al.  Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease , 2016, Clinical Rheumatology.

[17]  R. Hubbard,et al.  In-Hospital Mortality after Surgical Lung Biopsy for Interstitial Lung Disease in the United States. 2000 to 2011. , 2016, American journal of respiratory and critical care medicine.

[18]  M. Roth,et al.  Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis–associated interstitial lung disease trials , 2015, Arthritis Research & Therapy.

[19]  Jonathan H. Chung,et al.  Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease , 2015, European Respiratory Journal.

[20]  V. Strand,et al.  Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) — Report from OMERACT CTD-ILD Working Group , 2015, The Journal of Rheumatology.

[21]  D. Lynch,et al.  An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features , 2015, European Respiratory Journal.

[22]  G. Washko,et al.  Detection of Rheumatoid Arthritis-Interstitial Lung Disease Is Enhanced by Serum Biomarkers. , 2015, American journal of respiratory and critical care medicine.

[23]  D. Lynch,et al.  Connective Tissue Disease-related Thoracic Disease. , 2015, Clinics in chest medicine.

[24]  R. Hubbard,et al.  Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. , 2015, The Lancet. Respiratory medicine.

[25]  G. Koch,et al.  A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials , 2015, European Respiratory Journal.

[26]  H. Hatabu,et al.  Biomarkers of Rheumatoid Arthritis–Associated Interstitial Lung Disease , 2015, Arthritis & rheumatology.

[27]  M. Strand,et al.  Pulmonary function and survival in idiopathic vs secondary usual interstitial pneumonia. , 2014, Chest.

[28]  A. Young,et al.  Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics--a large multicentre UK study. , 2014, Rheumatology.

[29]  H. Collard,et al.  Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. , 2014, Chest.

[30]  D. Hashimoto,et al.  Prognostic Factors for Myositis-Associated Interstitial Lung Disease , 2014, PloS one.

[31]  Joyce S Lee,et al.  Predictors of mortality in rheumatoid arthritis‐related interstitial lung disease , 2014, Respirology.

[32]  L. Richeldi,et al.  Cross-Disciplinary Collaboration in Connective Tissue Disease-Related Lung Disease , 2014, Seminars in Respiratory and Critical Care Medicine.

[33]  Ami A. Shah,et al.  Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials , 2013, Thorax.

[34]  Gordon Cooke,et al.  Rheumatoid Arthritis (RA) associated interstitial lung disease (ILD). , 2013, European journal of internal medicine.

[35]  Shandra L. Protzko,et al.  An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. , 2013, American journal of respiratory and critical care medicine.

[36]  T. Oury,et al.  Animal models of fibrotic lung disease. , 2013, American journal of respiratory cell and molecular biology.

[37]  J. Myers,et al.  Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). , 2013, Respiratory medicine.

[38]  Naftali Kaminski,et al.  Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. , 2013, The Lancet. Respiratory medicine.

[39]  K. Meyer,et al.  Surgical lung biopsy for the diagnosis of interstitial lung disease: a review of the literature and recommendations for optimizing safety and efficacy. , 2013, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[40]  Man Pyo Chung,et al.  Interstitial Lung Disease , 2012, Current opinion in pulmonary medicine.

[41]  K. Brown,et al.  Connective tissue disease-associated lung disease. , 2012, Immunology and allergy clinics of North America.

[42]  J. Behr,et al.  Hot of the breath: Mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good , 2012, Thorax.

[43]  I. Noth,et al.  Pathologic quantification of connective tissue disease-associated versus idiopathic usual interstitial pneumonia. , 2012, Archives of pathology & laboratory medicine.

[44]  A. Fischer,et al.  Interstitial lung disease in connective tissue disorders , 2012, The Lancet.

[45]  T. Colby,et al.  Rheumatoid lung disease: prognostic analysis of 54 biopsy-proven cases. , 2012, Respiratory medicine.

[46]  S. Birring,et al.  The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire , 2012, Thorax.

[47]  Richard J Martin,et al.  A novel model of rheumatoid arthritis-associated interstitial lung disease in SKG mice , 2012, Experimental lung research.

[48]  Sumit K. Shah,et al.  Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide , 2011, European Radiology.

[49]  J. Myers,et al.  Fibrosing Interstitial Pneumonia Predicts Survival In Patients With Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD) , 2011, Asian Test Symposium.

[50]  F. Castelino,et al.  The impact of rheumatological evaluation in the management of patients with interstitial lung disease. , 2011, Rheumatology.

[51]  P. Jones,et al.  Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire , 2010, Thorax.

[52]  J. Varga,et al.  Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management , 2010, Arthritis research & therapy.

[53]  S. West,et al.  Connective tissue disease-associated interstitial lung disease: a call for clarification. , 2010, Chest.

[54]  T. E. King,et al.  Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease , 2009, European Respiratory Journal.

[55]  H. Collard,et al.  Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. , 2009, Chest.

[56]  C. Meisel,et al.  Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients , 2009, Arthritis research & therapy.

[57]  R. Elashoff,et al.  Surfactant Protein D and KL-6 as Serum Biomarkers of Interstitial Lung Disease in Patients with Scleroderma , 2009, The Journal of Rheumatology.

[58]  D. Hansell,et al.  Interstitial lung disease in systemic sclerosis: a simple staging system. , 2008, American journal of respiratory and critical care medicine.

[59]  C. Hogaboam,et al.  Murine models of pulmonary fibrosis. , 2008, American journal of physiology. Lung cellular and molecular physiology.

[60]  K. Leslie,et al.  Pulmonary pathology of the rheumatic diseases. , 2007, Seminars in respiratory and critical care medicine.

[61]  A. Nicholson,et al.  Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. , 2007, American journal of respiratory and critical care medicine.

[62]  T. Mimori,et al.  Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. , 2007, Arthritis and rheumatism.

[63]  David A Lynch,et al.  Quantitative CT of fibrotic interstitial lung disease. , 2007, Chest.

[64]  P. Emery,et al.  A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. , 2006, Arthritis and rheumatism.

[65]  Charlie Strange,et al.  Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.

[66]  David A Lynch,et al.  Idiopathic interstitial pneumonias: CT features. , 2005, Radiology.

[67]  T. Nishikawa,et al.  Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. , 2005, Arthritis and rheumatism.

[68]  A. Nicholson,et al.  Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis , 2004, Histopathology.

[69]  I. D. Johnston,et al.  American thoracic society/European respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias , 2002 .

[70]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[71]  G. Stucki,et al.  Development and validation of a self-administered systemic sclerosis questionnaire (SySQ). , 1999, Rheumatology.

[72]  P. Tugwell,et al.  The OMERACT filter for Outcome Measures in Rheumatology. , 1998, The Journal of rheumatology.

[73]  D. Brown,et al.  Scleroderma Lung Disease , 1997, European Respiratory Review.

[74]  D. Whalley,et al.  Quality of life in rheumatoid arthritis. , 1997, British journal of rheumatology.

[75]  V. Steen Autoantibodies in systemic sclerosis. , 1996, Seminars in arthritis and rheumatism.

[76]  M. Collen Clinical research databases—A historical review , 1990, Journal of Medical Systems.

[77]  E. Everett,et al.  The tight skin mouse: an animal model of systemic sclerosis. , 2004, Clinical and experimental rheumatology.

[78]  J. Ware SF-36 health survey: Manual and interpretation guide , 2003 .

[79]  T. Colby,et al.  The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. , 2002, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.